Monday, 4 January 2016
Friday, 1 January 2016
Sunday, 6 December 2015
ASH 2015: Making the Case for Transplant with Dr. Sergio Giralt, MD - The Myeloma Crowd
ASH 2015: Making the Case for Transplant with Dr. Sergio Giralt, MD - The Myeloma Crowd
Ik houd de ontwikkelingen bij en denk na over mijn opties bij relapse.
Mijn dokter wil mij een kuur met lenalidomide en dexamethasone geven.
Ik denk aan een tweede stamceltransplantage.
Ik houd de ontwikkelingen bij en denk na over mijn opties bij relapse.
Mijn dokter wil mij een kuur met lenalidomide en dexamethasone geven.
Ik denk aan een tweede stamceltransplantage.
Saturday, 28 November 2015
Paper: Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status
Paper: Long-Term Survivors after Stem Cell Transplantation in Multiple Myeloma: Bone Marrow Minimal Residual Disease, PET/CT and Immunological Status
Results: Twenty patients (20/160; 12.5%) were alive and in continuous CR after ASCT beyond 5 years; nine (5.7%) remained in CR for more than 10 years. In the alloSCT group, 6 out 58 patients (10.3%) were in CR beyond 5 years (3 of them for more than 10 years). Remarkably, two patients were in CR after 20 and 28 years after ASCT and alloSCT, respectively.
I'm in CR for more than six years now. Already far beyond expectations.
Reason for optimism.
Results: Twenty patients (20/160; 12.5%) were alive and in continuous CR after ASCT beyond 5 years; nine (5.7%) remained in CR for more than 10 years. In the alloSCT group, 6 out 58 patients (10.3%) were in CR beyond 5 years (3 of them for more than 10 years). Remarkably, two patients were in CR after 20 and 28 years after ASCT and alloSCT, respectively.
I'm in CR for more than six years now. Already far beyond expectations.
Reason for optimism.
Monday, 9 November 2015
Subscribe to:
Posts (Atom)